Zhendong Chen

Active 2004–2026

Also published as
ZhenDong Chen
131
Papers
18,194
Citations
40
h-index
94
i10-index

Citations

Citations per year for Zhendong Chen1979: 1 citations1986: 1 citations1989: 1 citations2002: 1 citations2004: 2 citations2005: 3 citations2006: 2 citations2007: 3 citations2008: 7 citations2009: 23 citations2010: 59 citations2011: 58 citations2012: 89 citations2013: 66 citations2014: 81 citations2015: 83 citations2016: 66 citations2017: 87 citations2018: 81 citations2019: 308 citations2020: 517 citations2021: 664 citations2022: 888 citations2023: 775 citations2024: 1,530 citations2025: 856 citations2026: 18 citations1980–1985: no citations, so these years are not shown1987–1988: no citations, so these years are not shown1990–2001: no citations, so these years are not shown2003: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 2,416 citing papers, 29.9% of this breakdownUnited States: 1,244 citing papers, 15.4% of this breakdownJapan: 477 citing papers, 5.9% of this breakdownItaly: 439 citing papers, 5.4% of this breakdownSouth Korea: 296 citing papers, 3.7% of this breakdownGermany: 293 citing papers, 3.6% of this breakdownUnited Kingdom: 285 citing papers, 3.5% of this breakdownFrance: 257 citing papers, 3.2% of this breakdownTaiwan: 257 citing papers, 3.2% of this breakdownSpain: 249 citing papers, 3.1% of this breakdownCanada: 156 citing papers, 1.9% of this breakdownHong Kong: 152 citing papers, 1.9% of this breakdown
0%29.9%Other 19.3%

Fields

  • Medicine78.8%
  • Biochemistry, Genetics and Molecular Biology12.2%
  • Engineering2.8%
  • Immunology and Microbiology2.5%
  • Computer Science1%
  • Materials Science0.6%
  • Other2.1%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis12.7%
  • Cancer Immunotherapy and Biomarkers8.5%
  • Lung Cancer Research Studies4.9%
  • Cholangiocarcinoma and Gallbladder Cancer Studies4%
  • Cancer Mechanisms and Therapy3.6%
  • Lung Cancer Treatments and Mutations2.8%
  • Other63.5%

Coauthors

All papers

Open in search
  1. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sylvia Hartl, Maximilian J. Hochmair, Bernd Lamprecht, Michael Studnicka, Luís Alberto Schlittler, Fabrício Augusto Martinelli de Oliveira, Aknar Calabrich, Gustavo Girotto, Peo Dos Reis, Carlos Fausto Nino Gorini, Peo Rafael Martins De Marchi, Clarissa Baldotto, Cláudia Vaz de Melo Sette, Mauro Zukin, Nikolay Conev, Assen Dudov, Rumyana Ilieva, Krassimir Koynov, Rositsa Krasteva, Ivan Tonev, Spartak Valev, Violetka Venkova, Minghong Bi, Chengshui Chen, Yuan Chen, Zhendong Chen, Jian Fang, Jifeng Feng, Zhigang Han, Jie Hu, Yi Hu, Xing Li, Zongan Liang, Lin Zhong, Rui Ma, Shenglin Ma, Kejun Nan, Yongqian Shu, Kai Wang, Mengzhao Wang, Gang Wu, Nong Yang, Zhixiong Yang, Helong Zhang, Wei Zhang, Jun Zhao, Yanqiu Zhao, Caicun Zhou, Jianying Zhou, Xiangdong Zhou, Libor Havel, Vı́tězslav Kolek, Leona Koubková, Jaromı́r Roubec, Jana Skřičková, Milada Zemanová, C. Chouaïd, Werner Hilgers, H. Léna, Denis Moro‐Sibilot, G. Robinet, Pierre-Jean Souquet, Jürgen Alt, Helge Bischoff, Christian Grohé, Eckart Laack, Susanne Lang, Jens Panse, Niels Reinmuth, Christian Schulz and 146 more - The Lancet 2019 cited by 2,199

  2. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Linna Wang, Linna Wang, Ahmed O. Kaseb, Arndt Vogel, Shukui Qin, Shukui Qin, Shukui Qin, Ahmed O. Kaseb, Arndt Vogel, Shanzhi Gu, Arndt Vogel, Zhenggang Ren, Xiaoyan Lin, Zhenggang Ren, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Jianping Xiong, Wei Li, Yajin Chen, Yong Zeng, А. В. Султанбаев, Monika Pazgan−Simon, Margaryta Pisetska, Davide Melisi, Margaryta Pisetska, Yurii Osypchuk, Ivan Sinielnikov, Tsai‐Sheng Yang, Liang Xiao, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Kangsheng Gu, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bożena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, M. Nechaeva, Chia‐Jui Yen, Wei‐Wen Su, Yen‐Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gómez-Martín, Min‐Hee Ryu, Hansang Kim, Jeehyun Kim, Oleg Zarubenkov and 38 more - The Lancet 2023 cited by 679

  3. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Gao‐Jun Teng, Yanru Qin, Jinhai Wang, Feng Xia, Guowen Yin, Yong Yang, Mingxia Chen, Yan Wang, Hui Zhou, Jia Fan - The Lancet Oncology 2021 cited by 1,115

  4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2008 cited by 5,842

  5. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rudolf Stauber, Matthias Pinter, Markus Peck‐Radosavljevic, Jochen Decaestecker, Pieter‐Jan Cuyle, Gontran Verset, Hans Van Vlierberghe, Sérgio de Azevedo, Livia Andrade, Ademar Cunha Júnior, Luiza Dib Batista Bugiato Faria, Cheng Tzu Yen, Leandro M. Colli, Jamil Asselah, Petr Kavan, Vladimir Marquez, Mayur Brahmania, Qiang Li, Bao-Cai Xing, Yabing Guo, Zhendong Chen, Haitao Zhao, Tao Peng, Liming Wang, Lu Wang, Hongming Liu, Feixiang Wu, Lun–Xiu Qin, Qichang Zheng, Jieer Ying, Haitao Li, Tianfu Wen, Shukui Qin, Xiaoyu Wen, Yunpeng Liu, Minshan Chen, Boqing Wang, Yuxian Bai, Yifu He, Hong Zhao, Dong Zhou, Chaoliu Dai, Gao‐Jun Teng, Shuzhong Cui, Yi Gao, Xizhi Zhang, Zheng Lu, Tao Yin, Youming Ding, Weidong Jia, Yongxiang Xia, Beicheng Sun, Qiang Xia, Yufeng Yuan, Hui‐Chuan Sun, Xuetao Shi, A. Guzmán, Luis Corrales, Zdeněk Král, Peter Priester, Eugen Kubala, Jean Frédéric Blanc, Marc Bourlière, Jean Marie Péron, Christophe Borg, Jean–Pierre Bronowicki, Nathalie Ganne, Thomas Decaens, Thomas Uguen, Alexandra Heurgué and 109 more - The Lancet 2023 cited by 488

  6. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ESCORT-1st Investigators, Xianglin Yuan, Dong Ma, Emily Liu, Feng Ye, Tianshu Liu, Xiuwen Wang, Likun Liu, Bing Xia, Fengming Ran, Sanyuan Sun, Zhanhui Miao, Jun Bie, Yong Gao, Junyan Yu, Li Chen, Yifu He, Wei Ren, Suxia Luo, Guangqiang Zhao, Youen Lin, Long Chen, Zhiyuan Guo, Chunhong Hu, Ying Wang, Nong Xu, Baofu Chen, Xianbao Zhan, Yuping Chen, Hongda Lu, Shukui Qin, Guolei Wang, Liming Chen, Li Bai, Jingdong Zhang - JAMA 2021 cited by 801

  7. Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lin Wen, Tao Zhang, Hakan Harputluoğlu, İrfan Çiçin, Guosheng Feng, Yanrong Hao, Kejing Ying, Ping Sun, Aihong Zhong, Guangyu An, Yan Wang, Chun Chen, Sheng Yang, Zhendong Chen, Konstantin Penkov, Yuriy Semegen, Oleg Kobziev, Feng Luo, Peiguo Cao, Zhixiong Yang, Min Fan, Wen Li, Robert Mróz, А. Л. Акопов, Tuncay Göksel, Mahmut Gümüş, Wenlei Zhuo, Jian Fang, Hui Zhao, Lin Zhong, Yanping Hu, Yarong Li, Shuqun Zhang, Jiuwei Cui, Н. В. Коваленко, Çağatay Arslan, Devrim Cabuk, Alev Türker, Igor Bondarenko, Yevhen Hotko, O. Goloborodko, Dongji Chen, Mengzhao Wang, Zhuang Yu, Jun‐Guo Lu, Liyan Jiang, Hao Xiong, Davit Giorgadze, Sergey Orlov, Ahmet Bılıcı, Ivan Sinelnikov, Gongyan Chen, Yue Lu, Xiaoli Zhu, Liqin Lu, Mariam Zhvania, Małgorzata Ułańska, Igor Lifirenko, Timur Andabekov, Maria Smagina, Fedor Moiseenko, Yüksel Ürün, Ligong Nie, Bangwei Cao, Zhenyu You, Haixin Huang, Shenpeng Ying, Alexandre Tavartkiladze, Tariel Kitiashvili, Amiran Matitashvili and 9 more - JAMA 2022 cited by 456

  8. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhanhui Miao, Meili Sun, Conghua Xie, Ying Liu, Qifeng Wang, Lina Zhao, Qi Li, Canhong Huang, Ke Jiang, Kunyu Yang, Daojun Li, Yunpeng Liu, Zhitu Zhu, Rixin Chen, Liqun Jia, Wei Li, Wangjun Liao, Hongxu Liu, Daiyuan Ma, Jie Ma, Yanru Qin, Zhihong Shi, Qichun Wei, Ke Xiao, Yan Zhang, Ying Zhang, Xin Chen, Guanghai Dai, Jianxing He, Junhe Li, Guanghui Li, Yong Liu, Zhihua Liu, Xianglin Yuan, Junping Zhang, Zhichao Fu, Yifu He, Fang Ju, Zheng Liu, Peng Tang, Tiejun Wang, Weibo Wang, Jing Zhang, Xianming Luo, Xiongwen Tang, Rena May, Hui Feng, Sheng Yao, Patricia Keegan, Rui‐Hua Xu, Feng Wang - Cancer Cell 2022 cited by 565

  9. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Feng Peng, Gang Wu, Nong Xu, Lin Zhao, Dong Ma, Shukui Qin, Wei Ren, Enxiao Li, Hongda Lu, Yueyin Pan, Jianping Xiong, Ying Yuan, Yuxian Bai, Lei Chen, Yi Hu, Li Zhang, Yong Gao - The Lancet Oncology 2020 cited by 584

  10. Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 189

  11. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial

    Authors: , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 638

  12. Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 414

  13. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , for the RATIONALE-302 Investigators - Journal of Clinical Oncology 2022 cited by 306

  14. Circumventing drug resistance in gastric cancer: A spatial multi-omics exploration of chemo and immuno-therapeutic response dynamics

    Authors: , , , , , , , , , , , , , , , , , , , - Drug Resistance Updates 2024 cited by 66

  15. First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wei Yan, Yingying Yang, Zhi Liu, Yufeng Peng, Bill Fanslow, Xian Huang, Li Zhang, Hongyun Zhao - Journal of Hematology & Oncology 2023 cited by 50

  16. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Laiyu Liu, Xingya Li, Jun Chen, Rui Ma, Yanzhen Guo, Ping Sun, Panwen Tian, Yueyin Pan, Zhe Liu, Peiguo Cao, Lieming Ding, Yang Wang, Xiaobin Yuan, Pengxiang Wu - The Lancet Respiratory Medicine 2023 cited by 71

  17. SKB264 (TROP2-ADC) for the treatment of patients with advanced NSCLC: Efficacy and safety data from a phase 2 study.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 32

  18. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , - Journal of Hematology & Oncology 2020 cited by 137

  19. Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer 2021 cited by 70

  20. Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 54

  21. Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy

    Authors: , , , , , , , , , - European Journal of Medicinal Chemistry 2023 cited by 33

  22. EvidenceNet: Evidence Fusion Network for Fact Verification

    Authors: , , , , , , - Web Conference 2022, WWW 2022 cited by 21

  23. Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer

    Authors: , , , , , , , , , , - European Radiology 2018 cited by 215

  24. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 111